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Adolescent patients who require the care of a nephrologist
present with a variety of challenges. For the treating
physician, it is important to be competent in relevant
principles of adolescent physiology, such as somatic growth
and puberty. It is also essential to be familiar with the stages
of adolescent emotional and intellectual development,
and their influence on behavior and adherence. Patients
transitioning from pediatric nephrology may experience
difficulties adjusting to the adult care system. Although the
renal pathology of adolescents has more in common with
that of adults than that of prepubertal children, there
are unique epidemiological, diagnostic, and treatment
approaches to these patients that should be considered.
Membranous glomerulonephritis and diabetic nephropathy
are rare in adolescents, whereas IgA and systemic lupus
erythematosus are often important differential diagnoses.
Despite all of the challenges posed by adolescents, there is a
real prospect of intervening early in the course of chronic
kidney disease with the potential to alleviate long-term
morbidity.
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When adolescent patients are referred to a nephrologist,
multiple issues may interfere with the provision of appro-
priate medical care, both for physicians and patients
alike. Peter et al.1 reported in a survey among internists
that, aside from the need for explicit pediatric expertise
regarding congenital and childhood-onset conditions, a
variety of psychosocial problems were seen as barriers to
care, such as the degree of family involvement, patient
maturity, and developmental concerns, as well as obtaining
financial support to care for patients with complex condi-
tions. Adolescents transitioning from pediatric to adult
nephrology and their parents may feel lost in the new
autonomous and efficiency-driven environment of adult
care.2 Not uncommonly, transition of care can meet with
resistance from both patients and parents, manifesting in
missed appointments and failure to follow through with care
instructions. Adolescents with new onset of renal conditions
can be similarly predisposed to nonadherence, lack of follow-
up, and, ultimately, higher morbidity. At the same time, early
presentation offers many opportunities for the clinician,
particularly the prevention of long-term sequelae of chronic
renal disease and its treatment. In the following review, we
discuss both the unique challenges and specific opportunities
of caring for adolescent nephrology patients.
PHYSIOLOGY OF ADOLESCENCE
Pubescent adolescents experience major physiological, cogni-
tive, and psychosocial changes. These include a somatic
growth spurt, the onset of reproductive capacity, appearance
of secondary sexual characteristics, as well as important steps
in intellectual and psychosocial development. The principal
endocrine mechanism driving this process is the neuroendo-
crine gonadotropin–gonadal axis. In addition to the visible
changes of puberty, nearly every organ system undergoes
a process of mainly gender-specific maturation, which
has important implications for the course of renal disease,
its treatment, and disease prevention (Figure 1). It is well
known that with the onset of puberty, males have elevated
blood pressures as compared with age-matched females, and
are more likely to develop hypertension.3 This relationship
reverses after menopause. Among the proposed mechanisms
to explain this observation are a testosterone-dependent
increase in renin activity and direct tubular effects of
testosterone such as increased expression of the ENaC
channel.3,4 Estrogens, on the other hand, can decrease blood
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pressure by attenuating smooth muscle constriction, both
through nitric oxide release as well as endothelium-
independent mechanisms.5 In addition to hypertension,
several chronic renal diseases seem to progress faster in
males.3 Estrogen reverses numerous profibrotic effects of
transforming growth factor-b, such as increased type IV
collagen synthesis, whereas testosterone increases prolifera-
tion of mesangial cells and stimulates collagen synthesis.3,6
Other hormonal changes of puberty, such as growth
hormone and insulin-like growth factor-I release, have the
potential to accelerate renal disease through transforming
growth factor-b activation, as evaluated for diabetic nephro-
pathy.7 Somatic growth is mediated by the growth hormo-
ne–insulin-like growth factor-I axis. In adolescents with
chronic renal failure, the response to these growth signals is
blunted, especially at the insulin-like growth factor-I level.8
ADHERENCE
As with somatic growth and maturation, intellectual and
psychosocial skills undergo equally profound changes during
adolescence. Physicians must take each adolescent’s stage
of development in these areas into account when formulating
an approach to a medical problem, especially with respect to
the patient’s understanding of and adherence to medical
instructions (Figure 2). Nonadherence is a very common and
complex phenomenon among adolescents with chronic
diseases. It can manifest as failure to fill prescriptions, delay,
or omission of doses, failure to follow through with medical
advice, and poor attendance at appointments. There are a
variety of reasons for adolescent nonadherence, one of the
most important being their limited degree of insight into
renal disease and their unwillingness to accept the implica-
tions of their condition. Both are dependent on intellectual
and emotional maturity.2 Future-oriented and complex
abstract thinking usually emerges only during late adoles-
cence and early adulthood. These abilities are critical in
adopting behaviors that support the successful management
of a chronic disease that requires adherence to a treatment
regimen. Mid-adolescence, on the other hand, is charac-
terized by susceptibility to peer pressure, defiance of
authority, risk-taking behavior, feelings of invulnerability,
and the tendency to revert to concrete rather than abstract
thinking in stressful situations, all of which interfere with
adherence.9 As rates of development differ among indivi-
duals, it can be very challenging to accurately assess a given
patient’s level of maturity, especially when advanced social
interaction skills and the desire to give pleasing answers may
be deceiving. In pediatric nephrology, the issue of non-
adherence is most studied in the setting of renal transplanta-
tion, with nonadherence to immunosuppressive medications
being the single most common cause of renal graft rejection
and failure, especially in adolescents.10 Our center has
dedicated a major effort to reducing nonadherence in the
adolescent transplant population.
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Figure 1 |Puberty and the kidney. Follicle-stimulating hormone (FSH), growth hormone (GH), growth hormone releasing hormone
(GHRH), gonadotropin-releasing hormone (GnRH), insulin-like growth factor-I (IGF-I), luteinizing hormone (LH), nitric oxide (NO),
renin–angiotensin system (RAS), transforming growth factor-b (TGF-b).
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Assessment of adherence
The first step in addressing nonadherence is accurately
determining a patient’s adherence status of a patient. Before
surgery, each patient and family are evaluated by a
psychologist and a social worker who can screen and identify
risk factors for nonadherence. Our center has developed a
standardized protocol for conducting these evaluations.11 It is
important to realize that self-reports by patients and family
members tend to overestimate adherence levels. However,
accuracy can be increased by using semi-structured inter-
viewing, such as the Medical Adherence Measure, which
assesses a patient’s knowledge of prescribed regimens, actual
behavior, obstacles to adherence, organizational skills, and
level of family support. The way a question is framed can
influence the accuracy of the answer received. Asking ‘Do
you take all your medications?’ frequently generates a
non-specific ‘yes,’ whereas ‘How many times have you missed
your prednisone in the past week?’ will yield a concrete
number. Checking on the status of pharmacy refills and
asking patients to bring medication bottles to appointments
for pill counts can also be useful. More objective measures
can provide additional information to help clinicians identify
nonadherence in an individual patient, gauge its severity,
understand factors influencing level of adherence, and devise
interventions that lead to improvement. Biomedical markers
allow a nephrologist to rate adherence based on drug assays
that quantify serum levels of medications and compare them
with results expected if a patient were adherent to the
prescribed regimen. However, it is important to note that
drug levels suggestive of nonadherence may be influenced by
medical complications, just as subjective reporting can be
skewed by socially desired answers. For example, decreased
dietary intake during a viral illness can increase the
absorption of tacrolimus and produce higher drug levels.
Simons et al.12 recently published a reporting system
combining both biomedical markers as well as subjective
reporting. The treating physician needs to combine all
available sources of information to arrive at the most
accurate assessment of a patient’s adherence status.
Intervention strategies
Once nonadherence is confirmed, interventions to improve
adherence should be tailored to the individual patient and
family situation. Education regarding the nature of the
disease and the relationship between a prescribed regimen
and the medical outcome, including the negative effects of
nonadherence, can be helpful for patients who lack under-
standing. It is important to ensure that the information is
delivered in a manner appropriate to the patient’s develop-
mental and cognitive status—pictures, charts, and simple
language can be helpful for younger or less mature patients—
and is repeated on multiple occasions. Practical recommen-
dations can also be beneficial with regard to organizing
medication administration, such as using a weekly pill box
and keeping medications in a single, convenient location.
Streamlining medication regimens, by reducing the overall
number of medications or adjusting dosage times or forms
(pills versus liquids), can also help, as more complex
regimens have been associated with nonadherence. Behavioral
strategies can be offered, such as using reminders in the form
of notes posted in the home, watch alarms, or calendars.
Psychosocial factors must also be considered when non-
adherence becomes a problem. Patients who are depressed or
anxious, who have psychological issues such as attention
deficit disorder, or whose families are stressed, conflictual, or
otherwise poorly functioning, should be referred for mental
health services. Table 1 provides a summary of the main
points from our center’s experience.13 We would encourage
adult nephrologists working with adolescent patients to
keep parents involved, as it is probably one of the most
effective measures available to physicians trying to maintain
adherence.
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Figure 2 |Adolescent cognitive and psychosocial development.
Upper panel—cognitive development; lower panel—psychosocial
development. The age range for each phase may vary; in particular,
with chronic diseases, significant delay may occur. To control
the problem of medical adherence, it is important to adjust to
the cognitive abilities and behavioral patterns of adolescents.
Adapted from Bell et al.9
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Transitioning care
Transition of medical care from a pediatric to an adult
nephrologist can, at times, be difficult. Not uncommonly,
patients will miss scheduled appointments with their adult
providers or try to return to pediatric care (for example, by
presenting to the emergency room of their pediatric hospital).
In our experience, parents also have difficulties during the
transition. Parents frequently are reluctant to push chronically
ill children toward a more age-appropriate level of indepen-
dence, influenced by feelings of guilt or a fear that the
youngster will not be able to manage his or her own health care
needs. In addition, transitioning to an adult nephrologist can
make parents feel powerless, out of control, and excluded. They
are, by law, not entitled to freely access confidential medical
information once their children reach the age of majority, and
the unwieldy process of gaining consent to receive firsthand
explanations from the patient’s physician does not easily fit
into the fast-paced and efficiency-driven operation of adult
medical care. At the same time, the autonomy-centered adult
medical environment can make adolescent adherence problems
much more difficult to address, especially if more invasive
control mechanisms become warranted. The subject of
transitioning from pediatric to adult medical providers has
been reviewed by Bell et al.9 and other authors. We would like
to add that in our experience, extending the involvement of
parents into young adulthood, while gradually shifting the
responsibility to the patient, should be considered. This will
not only encourage the parents’ cooperation with transitioning
but also use them as vital tools in addressing the significant
challenge of adolescent nonadherence.
RENAL PATHOLOGY OF ADOLESCENCE
Adolescent patients usually are referred with findings of
macro- or microscopic hematuria, along with proteinuria,
hypertension, edema, or impaired renal function. Although
the spectrum of underlying renal pathology is not very
different from that of young adults,14 it is important to
realize the differences that do exist and their implications.
IgA nephropathy
IgA nephropathy can affect all ages; however, it has a peak
incidence in the second and third decades of life. It is
remarkable for its very wide range of presenting clinical
features and variable disease progression after diagnosis.
Important risk factors for progression to end-stage renal
disease (ESRD) include an elevated creatinine, proteinuria
41 g/day, and hypertension.15 Young age has been shown by
multiple investigators to be a good prognostic marker
regarding the risk of developing ESRD, whereas older age is
an independent adverse risk factor.16
Acute poststreptococcal glomerulonephritis
Acute poststreptococcal glomerulonephritis has changed its
epidemiological pattern over the years. A study by Ilyas and
Tolaymat17 reported that pharyngitis has replaced impetigo
as the predominant cause of acute poststreptococcal
glomerulonephritis, and that the median age has risen from
4.25 to 7 years, with an increasing number of cases presenting
as adolescents and adults. The overall prognosis for recovery
from acute poststreptococcal glomerulonephritis in children
and adolescents remains excellent.
Rapidly progressive glomerulonephritis
Rapidly progressive glomerulonephritis (RPGN) is a severe
form, usually defined by more than 50% of the glomeruli
showing crescent formation.18 If left untreated, RPGN may
lead to renal failure within a few weeks or months. Although
RPGN can, in principle, arise from any inflammatory
glomerulonephritis, it is very commonly caused by anti-
neutrophil cytoplasmic autoantibodies-mediated glomerulo-
nephritis, particularly in the elderly. In adolescents, it may be
seen in IgA nephropathy, Henoch–Scho¨nlein purpura,
membranoproliferative glomerulonephritis, systemic lupus
erythematosus, and other causes of nephritis.14 Given the
grave prognosis of RPGN, many pediatric nephrologists will
initiate treatment even if renal biopsy reveals less than 50%
glomerular involvement.
Membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis can occur in
all ages, with a peak incidence in adolescence and
young adulthood, and is an important cause of ESRD in
the pediatric population. The idiopathic form predominates
in younger patients, whereas secondary membranoproli-
ferative glomerulonephritis is more common in adults.19
An important difference is the approach to treatment.
Unlike adult patients, children and adolescents with
membranoproliferative glomerulonephritis associated with
nephritic-range proteinuria may benefit from cortico-
steroid administration. In the International Study of Kidney
Disease in Children, alternate-day prednisone was adminis-
tered for 130 months, and 61% of the treatment group had
stable renal function at the end of the study period, as
compared with 12% of the controls.20 However, there is a
paucity of randomized controlled trial data available,
predating the now routine use of angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers for
renoprotection.
Table 1 | Top 10 suggestions for enhancing adolescent
adherence
1. Maintain an open and honest partnership.
2. Establish small, realistic goals.
3. Provide a range of acceptable options from which to choose.
4. Consider the patient and the family’s daily schedule and routine.
5. Give simple and concise prescriptions.
6. Deliver instructions in a clear, explicit form and repeat them.
7. Evaluate the patient’s understanding and recollection of instructions.
8. Use gradual implementation of complex regimens in small,
manageable steps.
9. Identify reminders in patient’s environment.
10. Involve all systems (family, psychosocial experts, school personnel).
Adapted from Zelikovsky and Walsh.13
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Alport syndrome
Alport syndrome, the most common form of hereditary
nephritis, is a function of impaired production or assembly
of the type IV collagen network, resulting in hematuria,
proteinuria, and progressive chronic kidney disease (CKD).
Bilateral sensorineural hearing loss and ocular defects are
commonly found. The diagnosis is frequently established
by biopsy, after patients present with hematuria and/or
proteinuria and a family history of hereditary nephritis. The
differential diagnosis of thin glomerular basement membrane
nephropathy is, in some cases, not easily distinguished, as
these patients are frequently heterozygous carriers for
autosomal recessive Alport syndrome.21 Alport syndrome is
associated with different gene mutations. In the more
common X-linked variant, the a-5 chain of collagen IV
(COL4A5) is affected. The autosomal forms are linked to
genes encoding for COL4A3 and COL4A4. Progression to
ESRD usually occurs in adulthood, but may arise during
adolescence. In the X-linked form, affected female adoles-
cents will usually have only microscopic hematuria with or
without proteinuria secondary to X-chromosomal lyoniza-
tion. Progression to ESRD is uncommonly reported in female
adolescents.22
Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) can
be recognized from fetal life to adulthood. ADPKD is a
systemic disease, with cysts occurring in the kidneys, liver,
pancreas, and other organs, including aneurysms of the
vasculature. In contrast to autosomal recessive polycystic
kidney disease, liver involvement is predominantly cystic and
hepatic failure is rare. Extrarenal manifestations of ADPKD
are uncommon in children and adolescents. Adolescents with
ADPKD may present with flank pain, hematuria, renal colic,
urinary tract infections, or hypertension, but they may be
asymptomatic. On imaging, multiple renal parenchymal cysts
are generally visible, and usually increase in size and number
with age. In general, the combination of a parent with
ADPKD and more than one cyst in a child is considered
diagnostic for ADPKD. Treatment is largely according to
symptoms. However, diagnosis of urinary tract infections can
be challenging, as the infection may be contained within a
cyst, not producing diagnostic pyuria. Furthermore, tradi-
tional pediatric first-line antibiotics, such as cephalosporins,
may be ineffective because of poor cyst penetration. A
sulfonamide or fluoroquinolone is usually preferred. Screen-
ing for extrarenal manifestations, such as intracranial
aneurysms, is not routinely recommended in children, and
magnetic resonance angiography is usually reserved for
symptomatic patients or those with a strong family history
of cerebrovascular disease.23
Nephrotic syndrome
Minimal change disease is highly prevalent in pediatric-onset
nephrotic syndrome, especially in prepubertal children, when
compared with that arising in adults. Although a variety of
authors have observed an increased prevalence of focal
segmental glomerulosclerosis in recent decades,24 treatment
patterns have remained consistent, including a consensus
that classic steroid-responsive minimal change nephrotic
syndrome does not warrant an initial biopsy. This does
not apply to postpubertal patients, given the increased
incidence of focal segmental glomerulosclerosis in adoles-
cence. Furthermore, a careful consideration of secondary
causes of nephrotic syndrome, such as malignancy, is advised.
Membranous glomerulonephritis is uncommon in children
and adolescents, accounting for only 3% of pediatric
nephrotic syndrome.25 It is usually seen in the context of
class V systemic lupus nephritis.26 Importantly, children and
adolescents may present with membranous lupus in the
absence of extrarenal manifestations of lupus disease.
Renal manifestations of sexually transmitted diseases
Sexually transmitted diseases and their treatment may
affect the kidney. Infections may be transmitted vertically
(congenitally) or horizontally. The three infections that
may lead to nephropathy include human immunodeficiency
virus, hepatitis B, and hepatitis C.27 One of the earliest signs
may be proteinuria. These diagnoses should be considered
in adolescent patients with sexual risk-taking behavior.
Although focal segmental glomerulosclerosis is the most
common HIV-associated nephropathy, other presentations
are possible, including minimal change disease, IgA, or a
lupus-like nephropathy.27 Renal replacement therapy through
dialysis and renal transplantation is possible and may prolong
life expectancy.
HYPERTENSION AND OTHER CARDIOVASCULAR RISK
FACTORS
Hypertension in young adults is a known risk factor for left
ventricular hypertrophy and coronary artery disease.28
Adolescents with stage II hypertension are at increased risk
of developing hypertensive encephalopathy, seizures, cerebro-
vascular accidents, and congestive heart failure. On the basis
of these observations, early detection and intervention in
children with hypertension is beneficial in preventing
long-term complications. Early intervention has significant
preventive potential, reducing the future burden of adult
cardiovascular disease. Current recommendations for diag-
nosis, evaluation, and treatment of childhood hypertension
are provided by the fourth report of the National High Blood
Pressure Education Program (NHBPEP) Working Group
on High Blood Pressure in Children and Adolescents.29 In
children and adolescents, unlike adults, secondary hyper-
tension is common and may arise because of a variety of
conditions, such as renal parenchymal or vascular disease.
Given the young age of the patients, it is necessary to
consider alternative causes, such as a previously undiagnosed
coarctation of the aorta. A very common reason for adoles-
cent referral is so-called ‘white coat hypertension,’ whose
accurate diagnosis largely depends on a detailed history and
age-appropriate physical exam. If initial screening suggests
Kidney International (2010) 77, 285–291 289
UH Beier et al.: Adolescent renal patients m in i rev iew
this diagnosis, ambulatory blood pressure monitoring is
recommended.30 To treat hypertension, angiotensin-convert-
ing enzyme inhibitors and angiotensin receptor blockers are
frequently used. With regard to adolescents, it is important to
consider issues of nonadherence and teen pregnancy (and the
need to stop any angiotensin-converting enzyme inhibitor
use), as well as the possibility of prerenal azotemia in patients
who are at risk for dehydration, such as from strenuous
exercise.14 Although hypertension is prevalent and impor-
tant, it alone cannot explain the increased incidence of adult
CKD, which has risen from 10 to 13.1%. Other important
factors include increasingly prevalent obesity and diabetes
mellitus.31 The Young Finns Study documented that early
exposure to cardiovascular risk factors may induce changes
in arteries that contribute to the development of athero-
sclerosis.32 Childhood obesity, a key risk factor in developing
these conditions, has become a major public health concern.
After a continued increase in prevalence in both adults
and children during the past decades, childhood obesity has
stabilized at 23% in African Americans and Mexican
Americans and at 12% in Caucasians.33 Given the grave
implications of obesity for renal disease and the benefits of
weight reduction, it is important that these problems be
addressed during office visits.
RENAL REPLACEMENT THERAPY
Management of CKD
There are a number of important differences in the manage-
ment of CKD in adolescents compared with adults. Foremost,
somatic growth is a central concern. Treatable causes
of growth retardation in adolescents include renal osteo-
dystrophy, metabolic acidosis, inadequate nutritional intake,
disturbances in the growth hormone–insulin-like growth
factor-I axis, and chronic treatment with steroid medica-
tions.34 Bone health in adolescents can present special
challenges, in particular, the unwillingness of many adolescent
patients to comply with a phosphorus-restricted diet. This
may result from both peer pressure and limited understanding
of the long-term implications of nonadherence. To maximize
somatic growth potential, protein intake is not restricted and
is maintained at the recommended daily allowance.35 In
addition, recombinant human growth hormone is widely
used. In a meta-analysis by Vimalachandra et al.,36 which
evaluated 15 randomized controlled trials involving 629
children, 28 IU/m2/week of recombinant human growth
hormone produced a 3.8 cm yearly height increase compared
with untreated patients. The response to treatment is,
however, impaired in patients on dialysis or with severely
delayed puberty. In addition, there are a variety of obstacles to
children and adolescents actually receiving daily recombinant
human growth hormone injections, including patient resis-
tance, parental refusal, and secondary hyperparathyroidism.
Peritoneal dialysis versus hemodialysis
From a purely medical perspective, there are many convin-
cing arguments in favor of peritoneal dialysis (PD) as
opposed to hemodialysis (HD). In the short term, PD has
been shown to be associated with superior outcomes
compared with HD.37 Furthermore, PD allows preservation
of vascular access, which is of particular importance to young
patients facing a lifetime of renal replacement therapy.
Children and adolescents on HD accumulate risk factors
leading to early and progressive coronary artery calcifica-
tions.38 In addition, nighttime administration of PD allows
children to attend school more regularly, and self-care
permits more flexibility with vacations and travel. Never-
theless, decisions regarding preferred dialysis modality for
any individual patient must take into account additional
considerations. Adolescents may find the prolonged treat-
ment time of nocturnal PD too intrusive into their social
time, leading to skipped or shortened treatments and poor
outcome from nonadherence. In addition, not all families
have the time, resources, or appropriate home setting to
support successful PD. Our center, in accordance with
Centers for Medicare & Medicaid Services requirements,
sends a social worker and a dialysis nurse on home visits to
carefully evaluate hygienic and psychosocial factors before
initiation of PD. If HD is indicated, it is important to
consider early placement of an arteriovenous fistula.37 For
young patients, this can be complicated by the paucity of
pediatric vascular surgeons. In a select subgroup of patients,
nocturnal HD may be suitable.
Transplantation
Since 1963, when Willard Goodwin first used corticosteroids
to achieve immunosuppression in renal allograft patients,
this medication has maintained a valuable role in organ
transplantation. However, the wide range of side effects is
substantial. Particularly in children and adolescents, growth
retardation, cushingoid features, and hyperlipidemia are of
concern and may lead to co-morbidities and nonadherence.
With the emergence of cyclosporine, followed by tacrolimus,
mycophenolate mofetil, and sirolimus, hope arose that the
role of steroids could be reduced. Although initial steroid-
sparing protocols resulted in increased rejection rates, more
recent trials using T-cell-depleting antibodies at induction
have been associated with little or no increase in rejection
rates and no difference in graft survival versus maintenance
prednisone, both in randomized and nonrandomized trials at
5–7-year follow-up.39 However, other immunosuppressive
agents can also have substantial side effects. Calcineurin
inhibitors are well known for their nephrotoxicity, making
the recipient susceptible to infections such as BK virus and
predisposing to malignancies. Apart from posttransplant
lymphoproliferative disorder, the high risk of skin cancer is of
particular concern, particularly in adolescent patients con-
cerned with body image. Consequentially, several groups
have developed protocols to minimize exposure to immuno-
suppressive agents. At our center, we have participated in a
calcineurin inhibitor-free regimen based on Campath-1H
(monoclonal anti-CD52 antibody),40 and in steroid with-
drawal and avoidance protocols.
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CONCLUSION
Although adolescent and adult nephrology patients are
similar in many ways, several prominent differences are
noted. First and foremost, it is important for the nephrologist
to recognize adolescent developmental stages and their
influence on behavior and adherence. Adherence is probably
the most profound problem that physicians have to address
in any adolescent patient with renal disease, and should be
a major focus of future research. Second, the epidemiology
of glomerular pathology is slightly different. Membranous
glomerulonephritis and diabetic nephropathy are rare,
whereas acute poststreptococcal glomerulonephritis, IgA
nephropathy, and Henoch-Scho¨nlein purpura are important
differential diagnoses to consider in adolescents. Third, the
physiology of the adolescent impacts the direction of
treatment on several levels, whether considering the implica-
tions of somatic growth in choosing to use growth hormone
or steroid-sparing regimens posttransplantation or calculat-
ing the likelihood of teen pregnancy before prescribing an
angiotensin-converting enzyme inhibitor. Finally, working
with adolescents provides an important and rewarding
opportunity for early intervention in the course of CKD,
with the potential to alleviate long-term morbidity.
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